about
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Adoptive immunotherapy against ovarian cancerPotential of afatinib in the treatment of patients with HER2-positive breast cancerVinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.Recent advances in the development of breast cancer vaccines.Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Underuse of anthracyclines in women with HER-2+ advanced breast cancer.Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.Role of trastuzumab in the management of HER2-positive metastatic breast cancer.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.Androgen receptor status predicts development of brain metastases in ovarian cancers.Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.Metastatic breast cancer subtypes and central nervous system metastases.Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.PARP Inhibitors in Ovarian Cancer.Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.Trastuzumab beyond disease progression: case closed?A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.Modeling ErbB2-p130Cas interaction to design new potential anticancer agentsTOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancersRole of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.Trastuzumab-related cardiotoxicity in the herceptin adjuvant trialOutcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapyTrastuzumab treatment in breast cancerA retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients
P50
Q26742047-C3790D76-D7EC-4EBE-99AD-915E5234520EQ26748905-036C3E8E-5207-4B0A-9B9D-8C865B7F45DAQ26999050-AA247404-0336-48BA-A8DD-95F556A7E949Q33354783-AA1089DA-716F-4924-B322-640CEB54A43FQ33370705-7362654E-D331-4AE0-A297-7930265C077FQ34379303-D6051AC1-3F14-42B0-BD72-7F8089D8CD3CQ34461019-D66E63A5-31D8-41F1-BB1C-E1DADA1DE47FQ34657786-B52D0E28-3AAC-4DF5-9B53-0D6CA47EBD72Q35584166-F6D4859B-38EA-4D98-A870-EBBEF101DD46Q36405652-E166C7D2-E9EA-44E9-9648-188D01F77695Q36710542-C9780F2E-988A-49F5-944A-C6D0A4575CA2Q36782465-814DD3EF-6B13-4918-82C3-FAC44402EAEEQ37295618-7BF18EA6-308C-4D1B-99C6-C1EFAD27CB3BQ37355020-F849CB9E-8F19-4286-8914-9D7879583688Q37355370-BF8805C4-79F4-47BC-A5DD-24526F81CE21Q37826199-0EBC1168-5E21-4B81-B555-884C8554D7EEQ38098973-D1587C26-393C-4849-845A-0B3C8E7757F9Q38809459-F27F23B6-17B8-4442-A8CD-1C6A2C6011A5Q39620638-1BC497D8-1083-46FE-AED6-D41682C8933CQ40810058-25A9BA30-29D6-42DF-AF49-531CCE791230Q41092731-EDF9EC9B-EB76-4021-BD75-42A7455DB8A5Q41134799-98177EC9-4ECA-4B01-9BA4-D5A820581946Q45286133-1072E696-72CD-46B7-9C67-5F12852F9267Q45968787-2F8227E3-E48A-4B7F-9DD8-B68F46B85043Q46295120-B1178F77-0898-4A01-BAF6-9E1DE8FEB76BQ47201278-5E66C1CE-5A7C-42CF-B4F2-F0EE24AAECA3Q48679305-6E8A2F6E-9652-4EC9-A575-D52B0AC54463Q50138637-A8E9E638-32FC-4CB7-B902-05D422575296Q52670215-CCEBD073-E210-46E7-93F1-0EF2368A9364Q54496663-E221D8C9-289D-4D61-A11A-F460DF5D92FFQ54588529-3794BBBB-0691-43CC-9864-3452CA1CCDF7Q54726081-831407E8-5702-48F9-946A-E2471FAB2870Q55302464-1219194E-52E7-45F0-BD15-15582B5A9AC3Q64092422-1C597ABC-87BC-40CD-B078-5C6BF6EC397EQ64239576-1B7F9576-66BC-4FD3-BF79-8CFD25ABCF0AQ64898254-D69AFFFF-6BD9-4BB6-90FC-06F6F32759A7Q81108795-81B9BD5C-2783-49EE-9085-4162AE6B0A6EQ83154089-DBD99657-360A-4F43-AFFB-D9F7E8073CF8Q83364734-4361E532-0324-4AF9-AFD8-76367909206EQ86932646-C6DA4034-8F54-48D4-80A2-017EBE651583
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giorgio Valabrega
@ast
Giorgio Valabrega
@en
Giorgio Valabrega
@es
Giorgio Valabrega
@nl
type
label
Giorgio Valabrega
@ast
Giorgio Valabrega
@en
Giorgio Valabrega
@es
Giorgio Valabrega
@nl
prefLabel
Giorgio Valabrega
@ast
Giorgio Valabrega
@en
Giorgio Valabrega
@es
Giorgio Valabrega
@nl
P106
P1153
10340665400
P31
P496
0000-0001-5444-6305